COMP <GO>
CAI vs LLY // RSI-14 & 200D SMA MOMENTUM
Caris Life Sciences Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: CAI 4
— LLY 9
▲ RSI-14 & 200D SMA MOMENTUM LEADER: LLY
LAST: $32.10 (-6.50%) • MKT CAP: $9.70B
rsi-technicals
58.8
LAST: $1,410.99 (-0.46%) • MKT CAP: $1.33T
rsi-technicals
71.0
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CAI VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CAI | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 83.64% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.40% | 32.36% | -27.96 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 95.0x | 36.4x | +58.61 | LLY | /valuation <GO> |
| Free Cash Flow Yield | 0.65% | 2.30% | -1.65 | LLY | /fcf-yield <GO> |
| Operating Margin | 5.60% | 40.21% | -34.61 | LLY | /operating-margins <GO> |
| Net Profit Margin | -8.40% | 31.90% | -40.30 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 97.00% | 45.51% | +51.49 | CAI | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 9.79 | 9.29 | +0.50 | CAI | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 9/9 | -1.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.81% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 58.8 | 71.0 | -12.20 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.91 | 0.51 | +0.40 | CAI | /macro-sensitivity <GO> |
| Forward P/E Multiple | 21.0x | 30.6x | -9.62 | CAI | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.70B | $1.33T | -$1.32T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CAI REV | LLY REV | CAI GROSS % | LLY GROSS % | CAI FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $812.0M | $65.18B | — | 83.0% | $66.9M | $16.81B |
| FY 2024 | $412.3M | $45.04B | — | 81.3% | -$253.6M | $8.82B |
| FY 2023 | $306.1M | $34.12B | — | 79.3% | -$289.9M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CAI // BETA 0.91
LLY // BETA 0.51